6949-76-4

Basic information

• Product Name: 1-[(methoxycarbonyl)amino]cyclopentanecarboxylic acid
• CAS NO: 6949-76-4
• Molecular Formula: C₈H₁₃NO₄
• Molecular Weight: 187.1931
• Mol File: 6949-76-4.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 359.4°C at 760 mmHg
• Flash Point: 171.2°C
• Density: 1.25g/cm³
• Vapor Pressure: 3.86E-06mmHg at 25°C
• Refractive Index: 1.506
• CAS DataBase Reference: 1-[(methoxycarbonyl)amino]cyclopentanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(methoxycarbonyl)amino]cyclopentanecarboxylic acid(6949-76-4)
• EPA Substance Registry System: 1-[(methoxycarbonyl)amino]cyclopentanecarboxylic acid(6949-76-4)

Safety Data

• Hazardous Substances Data: 6949-76-4(Hazardous Substances Data)

Usage

Type of compound

Chemical compound

Derivative of

Cyclopentanecarboxylic acid

Use

Synthesis of pharmaceuticals and other organic compounds

Presence of functional groups

Methoxycarbonyl and amino groups

Role in production

Key intermediate in the production of various drugs

Potential applications

Pharmaceutical industry for the development of new drugs

Upstream product

• 1903-22-6 ethyl cyclopentylideneacetate 
• 120-92-3 cyclopentanone 
• 931-43-1 2-(cyclopentylidene)ethanol 
• 79-22-1 methyl chloroformate 
• 52-52-8 1-amino-1-cyclopentanecarboxylic acid 

Relevant articles and documents

Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere

The design, synthesis, and X-ray structural analysis of hybrid HIV-1 protease inhibitors (PIs) containing bis-tetrahydrofuran (bis-THF) in a pseudo-C2-symmetric dipeptide isostere are described. A series of PIs were synthesized by incorporating bis-THF of darunavir on either side of the Phe-Phe isostere of lopinavir in combination with hydrophobic amino acids on the opposite P2/P2′ position. Structure-activity relationship studies indicated that the bis-THF moiety can be attached at either the P2 or P2′ position without significantly affecting potency. However, the group on the opposite P2/P2′ position had a dramatic effect on potency depending on the size and shape of the side chain. Cocrystal structures of inhibitors with wild-type HIV-1 protease revealed that the bis-THF moiety retained similar interactions as observed in the darunavir-protease complex regardless of the position on the Phe-Phe isostere. Analyses of cocrystal structures and molecular dynamics simulations provide insights into optimizing HIV-1 PIs containing bis-THF in non-sulfonamide dipeptide isosteres.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.